Detail akcie Biomarin Pharma online

Business Summary: BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company that develops and commercializes therapies. The Company's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. BioMarin 's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa) and Voxzogo (vosoritide). BioMarin's clinical development programs include Valoctocogene roxaparvovec is an adeno associated virus (AAV5) vector drug development candidate designed to restore factor VIII plasma concentrations in patients with severe hemophilia A; BMN 307 is an AAV5 mediated gene therapy that is designed to normalize blood Phe concentration levels in patients with Phenylketonuria (PKU), and BMN 255 is a small-molecule therapy that is designed to treat primary hyperoxaluria type 1, a subset of chronic renal disease.
Financial Summary: BRIEF: For the six months ended 30 June 2022, Biomarin Pharmaceutical Inc revenues increased 7% to $1.05B. Net income increased from $30.3M to $148.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Gain on sale of nonfinancial assets increase from $0K to $108M (income), Amortisation of Intangibles decrease of 50% to $15.6M (expense).